{"id":"oxycodone-naloxone-prolonged-release-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone binds to mu-opioid receptors in the central nervous system to produce pain relief and is formulated as a prolonged-release tablet for chronic pain management. Naloxone, an opioid antagonist, is incorporated at a low dose that is poorly absorbed orally but becomes active if the formulation is compromised (e.g., crushed for injection), thereby deterring misuse while having minimal impact on the therapeutic opioid effect when taken as intended.","oneSentence":"Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed or dissolved.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:47.965Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic moderate to severe pain requiring prolonged opioid therapy"}]},"trialDetails":[{"nctId":"NCT02571881","phase":"PHASE4","title":"Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section","status":"UNKNOWN","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Constipation, Pain, Postoperative","enrollment":57},{"nctId":"NCT01885182","phase":"PHASE3","title":"Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-06-01","conditions":"Cancer, Pain","enrollment":232},{"nctId":"NCT02880475","phase":"PHASE1","title":"OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2014-06-01","conditions":"Chronic Pain","enrollment":30},{"nctId":"NCT00513656","phase":"PHASE2","title":"A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2007-09","conditions":"Cancer, Pain, Constipation","enrollment":230},{"nctId":"NCT01197261","phase":"PHASE2","title":"OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-09","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Pain","enrollment":120},{"nctId":"NCT00412100","phase":"PHASE3","title":"Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2006-04","conditions":"Pain","enrollment":""},{"nctId":"NCT01971632","phase":"PHASE3","title":"A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2005-01","conditions":"Subjects With Moderate to Severe, Chronic Nonmalignant Pain","enrollment":463},{"nctId":"NCT01438567","phase":"PHASE3","title":"A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-09","conditions":"Pain, Constipation","enrollment":270},{"nctId":"NCT00412152","phase":"PHASE3","title":"Oxycodone-naloxone in Relieving Opioid-related Constipation","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2006-01","conditions":"Pain","enrollment":""},{"nctId":"NCT01112644","phase":"PHASE3","title":"Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-04","conditions":"Moderate to Severe Idiopathic RLS With Daytime Symptoms","enrollment":205},{"nctId":"NCT00902837","phase":"PHASE3","title":"OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-05","conditions":"Chronic Osteoarthritis","enrollment":181},{"nctId":"NCT01918098","phase":"PHASE3","title":"Targin for Non-cancer Pain","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2013-09-01","conditions":"Non Cancer Pain","enrollment":230},{"nctId":"NCT02321397","phase":"PHASE2, PHASE3","title":"To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2014-11","conditions":"Malignant Pain, Non-malignant Pain","enrollment":155},{"nctId":"NCT02573922","phase":"PHASE4","title":"Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-05","conditions":"Constipation","enrollment":180},{"nctId":"NCT01014559","phase":"PHASE3","title":"Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients","status":"TERMINATED","sponsor":"Mundipharma SAS","startDate":"2010-02","conditions":"Constipation, Pain","enrollment":225},{"nctId":"NCT01439100","phase":"PHASE3","title":"A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-10","conditions":"Parkinson's Disease With Severe Pain","enrollment":172},{"nctId":"NCT01167127","phase":"PHASE3","title":"Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain","status":"COMPLETED","sponsor":"Mundipharma Pharmaceuticals B.V.","startDate":"2009-06","conditions":"Pain","enrollment":113},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98},{"nctId":"NCT01083485","phase":"PHASE4","title":"OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty","status":"COMPLETED","sponsor":"Mundipharma Oy","startDate":"2010-03","conditions":"Post Operative Pain","enrollment":137},{"nctId":"NCT00784810","phase":"PHASE4","title":"A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2009-02","conditions":"Osteoarthritis, Back Pain","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone/Naloxone Prolonged Release tablets","genericName":"Oxycodone/Naloxone Prolonged Release tablets","companyName":"Mundipharma Research GmbH & Co KG","companyId":"mundipharma-research-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed or dissolved. Used for Chronic moderate to severe pain requiring prolonged opioid therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}